Polaris lung cancer clinical trial phase III analysis reached the highest standard, and drug certification is imminent
The Phase III interim analysis of the Polaris-KY (6550TW) clinical trial in the U.S. for lung mesothelial cancer (a type of lung cancer) was released on February 25, 2012. Based on current interim data, the overall success rate for the final trial is estimated to be above 80% (80-100%). The experts explained that this means …